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Rationale: 11C]PIB is the most widely used PET imaging marker for amyloid in dementia studies. In the major-
ity of studies the cerebellum has been used as a reference region. However, cerebellar amyloid may be pre-
sent in genetic Alzheimer's (AD), cerebral amyloid angiopathy and prion diseases. Therefore, we investigated
whether the pons could be used as an alternative reference region for the analysis of [11C]PIB binding in AD.
The aims of the study were to: 1) Evaluate the pons as a reference region using arterial plasma input function
and Logan graphical analysis of binding. 2) Assess the power of target-to-pons ratios to discriminate controls
from AD subjects. 3) Determine the test-retest reliability in AD subjects. 4) Demonstrate the application of
target-to-pons ratio in subjects with elevated cerebellar [11C]PIB binding.
Methods: 12 sporadic AD subjects aged 65±4.5 yrs with a mean MMSE 21.4±4 and 10 age-matched control
subjects had [11C]PIB PET with arterial blood sampling. Three additional subjects (two subjects with pre-
symptomatic presenilin-1 mutation carriers and one probable familial AD) were also studied. Object maps
were created by segmenting individual MRIs and spatially transforming the gray matter images into standard
stereotaxic MNI space and then superimposing a probabilistic atlas. Cortical [11C]PIB binding was assessed
with an ROI (region of interest) analysis. Parametric maps of the volume of distribution (VT) were generated
with Logan analysis. Additionally, parametric maps of the 60–90 min target-to-cerebellar ratio (RATIOCER)
and the 60–90 min target-to-pons ratio (RATIOPONS) were computed.
Results: All three approaches were able to differentiate AD from controls (pb0.0001, nonparametricWilcoxon
rank sum test) in the target regions with RATIOCER and RATIOPONS differences higher than VT with use of an
arterial input function. All methods had a good reproducibility (intraclass correlation coefﬁcient>0.83);
RATIOCER performed best closely followed by RATIOPONS. The two subjects with presenilin-1 mutations and
the probable familial AD case showed no signiﬁcant differences in cortical binding using RATIOCER, but the
RATIOPONS approach revealed higher [11C]PIB binding in cortex and cerebellum.
Conclusion: This study established 60–90 min target-to-pons RATIOs as a reliable method of analysis in [11C]
PIB PET studies where cerebellum is not an appropriate reference region.© 2012 Elsevier Inc. Open access under CC BY license.Introduction
Alzheimer's disease (AD) is characterized by amyloid plaques and
neuroﬁbrillary tangles in the brain. The clinical diagnosis is based on
the NINCDS-ADRDA (McKhann et al., 1984) and DSM 1 V criteria
(American Psychiatric Association, 1994). [11C]PIB or Pittsburgh com-
pound B, binds to ﬁbrillar amyloid with high afﬁnity and has been
widely used for in vivo PET imaging of amyloid load (Klunk et al.,C CyclotronUnit, Hammersmith
m. Fax: +44 2083831783.
n).
 license.2001). Several studies have shown a signiﬁcant increase in cortical
binding in AD subjects compared to controls (Edison et al., 2007;
Forsberg et al., 2007; Kemppainen et al., 2007; Klunk et al., 2004).
[11C]PIB binding is also signiﬁcantly increased in 50–70% of subjects
with mild cognitive impairment, 70–80% of subjects with dementia
with Lewy body disease, and a minority of subjects with Parkinson's
disease with later dementia (Edison et al., 2008; Forsberg et al.,
2007; Gomperts et al., 2008; Kemppainen et al., 2007). Although a
tauopathy, frontotemporal dementia cases can also on occasion
show a signiﬁcant amyloid load (Rabinovici et al., 2007).
In vitro studies suggest that thioﬂavins bind to ﬁbrillar amyloid
plaques and not to diffuse plaques (Klunk et al., 2001; Klunk et al.,
2003; Mathis et al., 2002; Mathis et al., 2003), however, the speciﬁcity
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2007). [11C]PIB studies using arterial in put analysis have demonstrat-
ed that there is no signiﬁcant difference between sporadic AD and
control subjects in cerebellar uptake (Edison et al., 2009; Price et al.,
2005). Price et al. (2005) suggested that the preferred method of
quantiﬁcation is to use ratio of the volume of distribution in the target
region over the volume of distribution in the cerebellar gray matter
where volumes of distributions are estimated through the Logan
graphical analysis with arterial input. Since then simpliﬁed methods
of analysis such as the Logan distribution volume ratio and the 60–
90 minute target tissue-to-cerebellum ratio RATIOCER methods have
been applied to clinical [11C]PIB studies and shown to be valid
(Drzezga et al., 2007; Edison et al., 2007; Engler et al., 2006;
Forsberg et al., 2007; Kemppainen et al., 2007; Lopresti et al., 2005).
In large clinical studies it is now usual to use 60–90 minute or 40–70
minute target-to-cerebellum ratios for quantitation.
Pathological studies in Prion disease have shown signiﬁcant amy-
loid deposits in the cerebellum (Mead et al., 2006; Watanabe and
Duchen, 1993). Additionally, a recent [11C]PIB PET study reported sig-
niﬁcant amyloid deposition in the cerebellum of familial AD subjects
(Kaufer et al., 2008; Klunk et al., 2007). Hereditary cerebral hemor-
rhage with amyloidosis, Icelandic type (HCHWA-I) is an autosomal
dominant disorder characterized by massive amyloid deposition
within small arteries and arterioles of leptomeninges, cerebral cortex,
basal ganglia, brainstem and cerebellum (Ghiso and Frangione, 2001).
Cerebellum may not be a suitable reference tissue in advanced or se-
vere AD cases where there might be not only diffuse but also dense
amyloid plaques in the cerebellar cortex. Given this, the cerebellum
is not always a suitable reference for the quantiﬁcation of [11C]PIB
PET. Therefore, an alternative reference region, the pons, is to be pro-
posed. Here, we set out to 1) Evaluate the pons as a reference region
using arterial plasma input function and Logan graphical analysis of
binding, 2) assess the power of target-to-pons ratios to discriminate
controls from AD subjects, 3) determine the test–retest reliability in
a cohort of sporadic AD subjects, 4) demonstrate the application of
target-to-pons ratio in subjects with elevated cerebellar [11C]PIB
binding.
Subjects and methods
Study population
Subjects were recruited from the Imperial College Healthcare NHS
trust, and the National Hospital for Neurology and Neurosurgery,
London, UK. 12 sporadic AD subjects, two additional presymptomatic
presenilin-1 mutation carriers (PS1 M146I and PS1 Y115C), one prob-
able familial AD (no genetic conﬁrmation), and 10 control subjects
were scanned. Majority of these scans were acquired as a part of pre-
viously published studies (Edison et al., 2007, 2009). All AD patients
met the DSM-IV and NINDS-ADRDA (McKhann et al., 1984) criteria
for a diagnosis of clinically probable AD. All subjects were assessed
neurologically which included taking a history from a carer and /or
relative and routine blood analysis and electroencephalography. All
subjects had detailed neuropsychometry including the Mini Mental
State Examination (MMSE) and tests of recognition, verbal and visual
memory, attention, executive / working memory, visuoconstruction,
language, letter ﬂuency and category ﬂuency. The inclusion and
exclusion criteria for AD subjects were as previously described
(Edison et al., 2007). Age matched healthy controls were recruited
from friends of the patients. The age of the AD subjects were 64.8±
4.9 years (mean±standard deviation), the MMSE scores of the sub-
ject were 20.7±3.9, and the duration of diagnosis was 14.5±
6.5 months. Eight subjects out of the thirteen AD subjects were
males. The age of the control subjects was 65.3±5.7 years, their
MMSE scores were 29.9±0.27. Six of the control subjects were
males. Another AD subject was a 55 year old lady who presented tothe memory clinic with difﬁculties in spelling, and failure to remem-
ber daily activities. Her husband noticed she was taking a long time to
do the daily chores and occasional spatial disorientation. She had an
MMSE score of 17/30, was able to recognize 3/4 famous faces, needed
prompting for picture description and was non-ﬂuent. Her cognitive
estimates were poor, she scored 2/3 in 3 stage commands and her
reading showed some paraphasic errors. She had ideomotor apraxia
of the right hand. Her nervous system examination was unremark-
able. An EEG showed low voltage EEG dominated by theta activity
with runs of theta and slow waves bilaterally, with anterior predom-
inance. There was very scanty alpha rhythm at 8 Hz. Unfortunately
the patient declined genetic studies. As the patient was not in touch
with the family for several years, the family history was unreliable.[11C]PIB PET
[11C]PIB was manufactured by Hammersmith Imanet (Cyclotron
building, Hammersmith Hospital). All subjects and the controls had
an intravenous bolus injection of 370 (±18) MBq of [11C]PIB and
scans were acquired on a Siemens ECAT EXACT HR+scanner as de-
scribed previously (Edison et al., 2009). All subjects except the two
subjects with presenilin-1 mutation had radial artery cannulation.
Continuous online blood sampling was performed for the ﬁrst
15 min, and discrete samples were taken according to the sampling
protocol summarized below.MRI
MRIs were obtained with a 1.5 Tesla GE scanner. A T1-weighted
volumetric MRI (3D T1 volume, pulse sequence RF-Fast, acquisition
times TR 30 ms, TE 3 ms, ﬂip angle 30°, FOV 25 cm, matrix
156×256, voxel dimensions 0.98×0.98×1.6 mm) was acquired for
co-registration with the PET images while T2-weighted images were
acquired to rule out any structural abnormality in AD and control
subjects.Generation of the plasma input function and parametric maps
For the generation of the plasma input functions, the time course
of the plasma-to-blood ratio, obtained from the ﬁrst six discrete arte-
rial samples at 5, 10, 15, 20, 30 and 40 min scan times was ﬁtted to a
sigmoidal function with four free parameters. Then arterial whole
blood activities recorded by the continuous detector system
(Ranicar et al., 1991) were corrected to obtain a plasma activity
curve for the ﬁrst 15 min of the scan. This curve was then combined
with the discrete plasma activity measurements at 20, 30, 40, 50,
60, 75 and 90 min to generate an input function describing the plas-
ma activity throughout the entire scan. An input function of the activ-
ity concentration due to unmetabolised [11C]PIB in plasma was then
created by multiplying the total plasma activity input function with
the function obtained from the ﬁt of a sigmoidal model for the parent
fraction in plasma to the eight measurements of the parent com-
pound during the scan. Finally, the time delay of the arrival of the ra-
dioactivity bolus at the peripheral sampling site relative to the brain
was determined (Hinz and Turkheimer, 2006). All calculations were
performed using Matlab® (The MathWorks, Inc., Natick, MA, USA)
on Sun UltraTM 10 workstations (Sun Microsystems, Inc., Santa
Clara, CA, USA).
The linear model developed by Logan et al. (Logan, 2000) has been
suggested as the preferred method of analysis for [11C]PIB. Parametric
images were generated with Receptor Parametric Mapping software
(Gunn et al., 1997). The parameter settings used were: 0.0005663 s−1
as the decay constant for 11C and 35 min linear time as the threshold
for the Logan analysis (Lopresti et al., 2005; Price et al., 2005).
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The [11C]PIB target region-to-cerebellar ratio image was created
by dividing the integrated 60–90 minute image by the integrated
60–90 minute value of cerebellar gray matter. Initially a 60–90 mi-
nute [11C]PIB sum image was created by integrating the activity col-
lected from 60 to 90 min in Matlab 6. This image was co-registered
to the individual's MRI using SPM 99. This coregistered image was
then spatially transformed into MNI space. Cerebellar activity concen-
tration was then calculated by sampling the 60–90 minute sum image
using the cerebellar gray matter object map (see below) in Analyze.
The 60–90 minute [11C]PIB add image was then divided by the
cerebellar activity concentration value to create a 60–90 minute
ratio (RATIOCER) image using image calculator in Analyze. RATIOCER
is also referred as SUVRCER. (Standard uptake value ratio using
cerebellum).60–90 minute target-to-pons ratio (RATIOPONS)
Anatomically pons is ventral to the cerebellum, rostral to the mid-
brain, and inferiorly the pons is continuous with the medulla oblon-
gata. The pons contains both gray and white matter. In creating
RATIOPONS, initially a 60–90 minute [11C]PIB image was generated
by integrating the activity collected from 60 to 90 min in Matlab 7.5.
This image was coregistered to the individual's MRI using SPM99. This
coregistered image was then spatially transformed into MNI space.
The pons was traced manually as a polygonal three-dimensional con-
tour on individual MRI images in MNI space, where the tracing reached
the edges of the pons. The regional activity concentration in the pons
was then calculated by sampling the 60–90 minute sum image using
the ‘pons object map’ in Analyze. The 60–90 minute add image was
then divided by the activity concentration value in pons to create a
60–90 minute ratio (RATIOPONS) image using image calculator in
Analyze. RATIOPONS is also referred as SUVRPONS (Standard uptake
value ratio using pons).Region of interest (ROI) analysis and deﬁnition of ROIs
Creation of object map
Weused statistical parametricmapping software (SPM99,Wellcome
Department of Imaging Neuroscience, UCL, London, UK; http: www.
ﬁl.ion.ucl.ac.uk/spm) to perform the following image pre-processing
steps. MRIs were segmented into gray matter, white matter and
CSF, and the gray matter images were thresholded at 50% probability.
These gray matter images were then spatially transformed into MNI
space. We convolved this binarised gray matter map with the latest
version of a probabilistic brain atlas (Hammers et al., 2003) to create
individualized object maps including that of cerebellum for each
subject.
Pons was manually traced as described above. We then sampled
[11C]PIB Logan VT, RATIOPONS, and RATIOCER images in the following
regions: frontal, temporal and parietal association cortices, anterior
and posterior cingulate, striatum, thalamus, pons and cerebellar
gray matter.Statistical analysis
Statistical interrogations of ROI data were performed using
SPSS for Windows version 14 (SPSS, Chicago, Illinois, USA). We
used the nonparametric Wilcoxon rank sum test to interrogate
a statistically signiﬁcant difference between AD and controls'
outcome measures Logan VT, RATIOCER, and RATIOPONS (α=0.05,
two sided).Percentage difference between the AD and control subjects were
then calculated as
δ %ð Þ ¼ AD−HCð Þ
HC
 100;
where, δ denotes percentage difference, AD denotes the cohort mean
parameter in the Alzheimer's disease subjects, and HC denotes the
cohort mean parameter in the control subjects.
The percentage variability
ABS AD2–AD1ð Þ= AD2 þ AD1ð Þ=2ð Þ100%
where λ denotes percentage variability, AD2 denotes the parameter
estimate in the second scan, AD1 denotes the parameter estimate in
the ﬁrst scan and ABS() refers to the absolute value.
SPSS for Windows version 14 was used to calculate the intraclass
correlation coefﬁcient (ICC) using one way random single measures
(Shrout and Fleiss convention) in 5 AD subjects. ICC was calculated as
ICC ¼ BSMSS−WSMSS
BSMSSþ n−1ð ÞWSMSS
where, BSMSS is the mean sum of squares between subjects, WSMSS
is the mean sum of squares within subjects, and n is the number of
repeated observations (n=2 in this test–retest paradigm). This coef-
ﬁcient estimates the reliability of the measurement and ranges
between -1 (no reliability, that is, BSMSS=0) and 1 (maximum
reliability, achieved in the case of identity between test and retest,
that is, WSMSS=0).
Results
Fig. 1 shows the [11C]PIB scan outcome parameters in a patient
group of 12 AD subjects and a cohort of 10 control subjects in six dif-
ferent target regions (anterior and posterior cingulate, striatum, fron-
tal, temporal and parietal cortices) and the two reference regions
considered (cerebellar gray matter and pons) using the arterial
input Logan VT (Fig. 1A), the target tissue-to-cerebellum ratio
RATIOCER (Fig. 1B) and the target tissue-to-pons ratio RATIOPONS
(Fig. 1C) as the outcome parameters.
For the two reference regions, Fig. 1A conﬁrms that there is no sig-
niﬁcant difference in the cohort mean VT for pons or cerebellum. In
both study groups, the pons VT exceeds that of cerebellum. As a gen-
eral observation, the cortical RATIOPONS values in Fig. 1C are lower
than the RATIOCER values in Fig. 1B. However, further visual inspec-
tion then also reveals that all these methods can provide a clear
group differentiation between AD and control subjects in the target
regions.
A quantitative assessment of the discriminatory power between
these two study groups is provided in Table 1. The minimum percent-
age group difference in the six target regions for the three outcome
measures considered was an increase of 57% in patients relative to con-
trols (in temporal cortex using the LoganVT target-to-cerebellum ratio).
The statistical signiﬁcance of the group difference in all six target
regions was conﬁrmed by the Wilcoxon rank sum test (pb0.0001). On
the other hand, for the two reference regions considered cerebellum
and pons, there were no statistically signiﬁcant differences between
the two groups for any of the three outcome measures. Taken together
these results conﬁrm the suitability of either cerebellum or pons as a
reference region for the group discrimination between controls and
AD subjects.
Table 2 shows the results on the reproducibility of the three
outcome measures as assessed by the group mean variability and
the intraclass correlation coefﬁcient (ICC) in a test–retest study
of ﬁve AD patients. The mean variability for any of the ﬁve cortical
target regions was at most 8.9% (Logan VT in the anterior
Fig. 1. Comparison of three different [11C]PIB outcome measures for the discrimination between a cohort of 12 AD patients (ﬁlled triangles pointing up) and a group of 10 control
subjects (open triangles pointing down).Individual data points are shown for six different target regions (anterior and posterior cingulate, striatum, frontal, temporal and parietal
cortices) and the two reference regions considered (cerebellum and pons).The outcome parameters are arterial input analysis Logan total volume of distribution VT (A), target
tissue-to-cerebellum ratio RATIOCER (B) and target tissue-to-pons ratio RATIOPONS (C). in Fig. 1A demonstrates the Logan VT in the young onset (possibly familial) AD. A statistically
signiﬁcant group difference between patients and controls was found in all six target regions for all three outcomemeasures (pb0.0001, two-sidedWilcoxon rank sum test withα=0.05).
1719P. Edison et al. / NeuroImage 60 (2012) 1716–1723cingulate and RATIOPONS in the frontal cortex, respectively). On
the whole, the mean variability was lowest for RATIOCER followed
by RATIOPONS in anterior cingulate, posterior cingulate, frontal andparietal cortex. Only in striatum, temporal cortex and cerebellum
the mean variability of Logan VT was smaller than that of
RATIOPONS.
Table 1
Discriminatory power between a group of 12 AD patients and a group of 10 control subjects by method and region.
Region Logan VT in ml/cm3 Logan VT target-to-cerebellum ratio RATIOCER RATIOPONS
Mean±SD Mean±SD Per cent
difference
Mean±SD Per cent
difference
Mean±SD Per cent
difference
Patients Controls Patients Controls Patients Controls Patients Controls
A-Cing 3.99±0.58 2.52±0.36 1.87±0.29 1.04±0.06 79.3 ⁎ 2.38±0.28 1.12±0.11 113.2 ⁎ 1.49±0.18 0.69±0.06 116.5 ⁎
P-Cing 4.12±0.58 2.51±0.36 1.93±0.28 1.04±0.04 85.3 ⁎ 2.36±0.30 1.09±0.05 115.4 ⁎ 1.49±0.21 0.68±0.09 118.0 ⁎
Striatum 3.92±0.40 2.68±0.36 1.83±0.17 1.11±0.05 64.9 ⁎ 2.13±0.11 1.10±0.04 93.4 ⁎ 1.35±0.11 0.68±0.06 98.3 ⁎
Frontal 3.83±0.54 2.47±0.38 1.79±0.24 1.02±0.05 75.4 ⁎ 2.17±0.24 1.09±0.07 98.7 ⁎ 1.37±0.18 0.67±0.06 102.9 ⁎
Temporal 3.44±0.60 2.46±0.36 1.60±0.21 1.02±0.03 57.6 ⁎ 1.97±0.27 1.07±0.04 84.4 ⁎ 1.24±0.19 0.66±0.06 87.1 ⁎
Parietal 3.61±0.59 2.46±0.38 1.70±0.31 1.02±0.04 66.8 ⁎ 2.16±0.27 1.09±0.05 99.2 ⁎ 1.36±0.18 0.67±0.06 102.3 ⁎
C'bellum 2.16±0.32 2.42±0.35 1±0 1±0 0 1±0 1±0 0 0.65±0.06 0.64±0.07 1.4
Pons 3.22±0.35 3.45±0.41 1.51±0.18 1.46±0.13 3.4 1.57±0.15 1.59±0.17 −1.5 1±0 1±0 0
Table 1 shows the percentage difference between 12 AD and 10 control subjects using three different outcome parameters (arterial input analysis Logan VT, target tissue-to-
cerebellum ratio RATIOCER and target tissue-to-pons ratio RATIOPONS) in six different target regions and the two reference regions considered.
The percentage difference was calculated as δ %ð Þ ¼ AD−HCð ÞHC  100 where, δ denotes percentage difference, AD denotes the cohort mean parameter in the Alzheimer's disease
subjects, and HC denotes the cohort mean parameter in the control subjects.
SD stands for standard deviation.
⁎ Denotes a statistically signiﬁcant group difference between patients and controls (pb0.0001, two-sided Wilcoxon rank sum test with α=0.05).
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come measures with a minimum ICC of 0.96 in the anterior cingulate
and even higher ICCs in the other ﬁve target regions. The ICC was
higher for RATIOPONS than for Logan VT in those regions where the
mean variability for RATIOPONS was lower than for Logan VT and
vice versa. As to be expected due to the absence of speciﬁc binding,
the RATIO methods performed poorly in terms of ICC for the assess-
ment of the other reference region (ICCPons=0.55 for RATIOCER and
ICCCerebellum=0.61 for RATIOPONS). Altogether, the mean variability
and the ICC in Table 2 conﬁrm for all three [11C]PIB outcome mea-
sures a reproducibility typical for brain PET studies.
A comparison of the three outcome measures in one AD subject
with noticeable elevated cerebellar [11C]PIB binding is shown in
Table 3. As shown in Table 3, the total volume of distribution VT
from Logan analysis with an arterial input was higher by more than
100% in the ﬁve cortical regions listed compared to the mean in the
control subjects. Of the two simpliﬁed methods considered, for
RATIOCER the values were only about 30% higher in the cortical re-
gions whereas for RATIOPONS the values were at least 100% higher in
the ﬁve cortical regions investigated. Furthermore RATIOPONS was
increased by 52% in the cerebellar gray matter, which is very similar
to the increase of the VT by Logan analysis.
Table 4 shows a comparison of the two simpliﬁed outcome param-
eters RATIOCER and RATIOPONS in two presymptomatic presenilin 1
mutation carriers who have a family history of familial Alzheimer's
disease. Both these subjects had an MMSE of 30. By comparingTable 2
Reproducibility of the three outcome measures by region assessed in a cohort of ﬁve AD pa
Region Logan VT RATIOCER
Per cent variability
Mean±SD
Intraclass correlation
coefﬁcient
Per cent variabilit
Mean±SD
A-Cing 8.9±4.5 0.88 5.7±5.4
P-Cing 8.1±4.8 0.87 4.2±2.8
Striatum 6.8±6.6 0.89 6.3±2.7
Frontal 7.8±3.8 0.87 3.2±1.7
Temporal 5.6±3.3 0.91 2.2±1.6
Parietal 8.0±3.2 0.83 2.6±1.6
C'bellum 4.8±4.1 0.95 0±0
Pons 8.0±8.5 0.88 8.1±5.8
Table 2 shows the percentage variability and the intraclass correlation coefﬁcient obtained i
different outcome parameters (arterial input analysis Logan VT, target tissue-to-cerebellum
and the two reference regions considered.
The percentage variability was calculated as ABS(AD2−AD1)/( (AD2+AD1)/2 )×100% whe
estimate in the ﬁrst scan and ABS() refers to the absolute value.
The intraclass correlation coefﬁcient was calculated as ICC ¼ BSMSS−WSMSSBSMSSþ n−1ð ÞWSMSS where BSMSS i
subjects, and n=2 is the number of repeated observations in this test–retest paradigm.
SD stands for standard deviation. NaN represents Not a Number.these two subjects with the group of ten controls, RATIOCER demon-
strated a much smaller effect size than RATIOPONS in the cortical
regions. Moreover, the second case FAD 2 would not have been
classiﬁed as PIB positive based on the RATIOCER. Both cases FAD 1
and FAD 2 have a more than 50% higher RATIOPONS in cerebellar
gray matter suggesting higher [11C]PIB binding in the cerebellum of
presenilin 1mutation carriers relative to the control cohort. Note that
these two subjects were not scanned with an arterial input function,
therefore no Logan VT are available.
A visual impression of parametric images generated with the
target-to-pons ratio approach is provided by Fig. 2. Fig. 2A shows a
control subject, Fig. 2B shows a sporadic AD subject, while Fig. 2C
shows the presenilin-1 mutation carrier FAD2 from Table 4. There ap-
pears a qualitative difference between the three cases shown. For the
control subject, only a few focal areas of increased binding in white
matter are visible whereas the [11C]PIB binding in this AD patient is
characterized by higher RATIOPONS values mostly in cortical gray mat-
ter with no apparent differences in the gray matter of the cerebellum.
An impression dominated by rather scattered spots of high [11C]PIB
signal not clearly associated with either gray or white matter is
given by the RATIOPONS parametric map of FAD2.
Discussion
In this study we evaluated the use of the target-to-pons ratio
RATIOPONS for the analysis of [11C]PIB brain PET scans. As comparatortients scanned twice.
RATIOPONS
y Intraclass correlation
coefﬁcient
Per cent variability
Mean±SD
Intraclass correlation
coefﬁcient
0.96 7.2±10.3 0.90
0.99 6.4±7.7 0.94
0.97 10.8±5.4 0.87
0.99 5.7±6.3 0.94
0.99 8.9±4.6 0.89
0.99 5.4±5.7 0.96
NaN 5.8±5.3 0.61
0.55 0±0 NaN
n a cohort of ﬁve AD patients each scanned on two occasions with [11C]PIB using three
ratio RATIOCER and target tissue-to-pons ratio RATIOPONS) in six different target regions
re AD2 denotes the parameter estimate in the second scan, AD1 denotes the parameter
s the mean sum of squares between subjects, WSMSS is the mean sum of squares within
Table 3
Comparison of the three outcome measures in a single AD subject with increased cerebellar [11C]PIB uptake.
Region Logan VT in ml/cm3 RATIOCER RATIOPONS
Single case
AD
Controls
Mean±SD
Per cent
difference
Single case
AD
Controls
Mean±SD
Per cent
difference
Single case
AD
Controls
Mean±SD
Per cent
difference
A-Cing 5.64 2.52±0.36 124 1.52 1.12±0.11 36 1.47 0.69±0.06 113
P-Cing 5.80 2.51±0.36 131 1.50 1.09±0.05 37 1.46 0.68±0.09 114
Striatum 4.99 2.68±0.36 86 1.25 1.10±0.04 13 1.21 0.68±0.06 77
Frontal 5.42 2.47±0.38 119 1.44 1.09±0.07 32 1.40 0.67±0.06 108
Temporal 5.08 2.46±0.36 107 1.35 1.07±0.04 27 1.32 0.66±0.06 100
Parietal 5.59 2.46±0.38 127 1.51 1.09±0.05 39 1.46 0.67±0.06 117
C'bellum 3.64 2.42±0.35 50 1 1±0 0 0.97 0.64±0.07 52
Pons 4.14 3.45±0.41 20 1.05 1.59±0.17 −34 1 1±0 0
Table 3 shows the percentage difference between a single case AD subject with increased cerebellar [11C]PIB uptake and a group of 10 control subjects using three different outcome
parameters (arterial input analysis Logan VT, target tissue-to-cerebellum ratio RATIOCER and target tissue-to-pons ratio RATIOPONS) in six different target regions and the two ref-
erence regions considered.
The percentage difference was calculated as δ %ð Þ ¼ AD−HCð ÞHC  100 where, δ denotes percentage difference, AD denotes the parameter estimated in the single case Alzheimer's disease
subject, and HC denotes the cohort mean parameter in the control subjects. SD stands for standard deviation.
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obtained with Logan graphical analysis of reversible binding using
the metabolite corrected arterial plasma input function (Price et al.,
2005) and the target-to-cerebellum ratio RATIOCER were used.
First, RATIOPONS was able to discriminate a group of 12 sporadic
AD patients from a cohort of 10 control subjects in ﬁve cortical target
regions and the striatum with high statistical signiﬁcance (pb0.0001,
nonparametric Wilcoxon rank sum test). Second, a test–retest repro-
ducibility study performed in ﬁve AD patients demonstrated the high
reliability of the RATIOPONS as an outcome measure with intraclass
correlation coefﬁcients (ICC) of 0.87 or higher in the same set of six
target regions. Overall, RATIOPONS gave higher ICCs than the arterial
input function Logan VT for the target regions though the ICCs were
still lower than those of RATIOCER. Third, from the study of a single
AD subject with elevated cerebellar [11C]PIB binding there is evidence
that RATIOPONS can be used for the analysis of [11C]PIB studies where
elevated cerebellar binding might be present. Furthermore, we suc-
cessfully used RATIOPONS for the [11C]PIB data analysis in two cases
of presenilin-1 mutation carriers and probable FAD where RATIOCER
failed to differentiate from the control mean values.
In one AD case, Logan analysis with metabolite corrected arterial
plasma input function showed elevated binding of [11C]PIB in both
cortex and cerebellum. The RATIOCER analysis detected only a smaller
difference compared to the RATIOPONS, which detected around two-
fold higher values in the cortical regions of this single AD subject
compared to the controls' mean values (Table 3). This subject de-
clined genetic analysis but may have a mutation accounting for the
early onset and rapid deterioration of the disease. Our two subjects
with presenilin-1 mutations, in the absence of memory loss, both
had higher RATIOPONS in the cortex and the cerebellum than the
mean control values whereas RATIOCER underestimated the [11C]PIBTable 4
Comparison of the two simpliﬁed outcome parameters RATIOCER and RATIOPONS in two sub
Controls
Mean±SD
First case FAD 1 Second case FAD 2
RATIOCER RATIOCER Per cent difference RATIOCER Per cent differenc
A-Cing 1.12±0.11 1.14 2.2 1.05 −5.9
P-Cing 1.09±0.05 1.43 30.7 1.13 3.3
Striatum 1.10±0.04 1.25 13.4 0.97 −12.0
Frontal 1.09±0.07 1.20 10.1 1.06 −2.7
Temporal 1.07±0.04 1.08 1.3 1.05 −1.6
Parietal 1.09±0.05 1.20 10.5 1.15 5.9
C'bellum 1±0 1 0 1 0
Pons 1.59±0.17 0.99 −37.8 1.04 −34.6
Table 4 shows the percentage difference between two pre-symptomatic PS1 mutation carrie
tissue-to-cerebellum ratio RATIOCER and target tissue-to-pons ratio RATIOPONS) in six differ
The percentage difference was calculated as δ %ð Þ ¼ AD−HCð ÞHC  100 where δ denotes percenta
disease subjects, and HC denotes the cohort mean parameter in the control subjects. SD stabinding differences (Table 4). Studies have examined the reproduc-
ibility of [11C]PIB using different methods of analysis (Aalto et al.,
2009; Edison et al., 2009; Engler et al., 2006; Lopresti et al., 2005;
Price et al., 2005) and have shown that reference tissue methods per-
form better than the arterial input method of analysis for discrimina-
tion of AD from healthy normals, while the target-to-cerebellum ratio
performed better than the other simpliﬁed methods of analysis in
terms of sensitivity and reproducibility (Yaqub et al., 2008). Here,
the target-to-pons ratio demonstrated high sensitivity for detecting
AD and gave comparable test–retest reproducibility to RATIOCER.
For a qualitative discussion of the [11C]PIB binding in gray matter
and white matter, respectively, tissue-time activity curves (TACs)
obtained in an AD patient (left) and in a control participant (right)
are presented in Fig. 3. In the healthy subject shown in Fig. 3B, the
early peaks in the TACs after bolus administration are highest for
the two gray matter regions cerebellum and temporal cortex. Consis-
tent with an about two fold higher blood ﬂow in gray matter than in
white matter, the early peaks of the white matter TACs sampled from
the centrum semiovale are only about half the height of the peaks of
the cerebellar TACs in both cases (Fig. 3A and Fig. 3B). Note the visible
reduction of the TAC peak height for the temporal cortex of the AD
subject in Fig. 3A relative to the peak height of the cerebellar TAC in
the same scan. This observation is in agreement with reported reduc-
tions of regional cerebral blood ﬂow in cortical areas of AD patients.
Both heights of the early peaks of the pons TACs in Figs. 3A and 3B
are substantially larger than those of the respective white matter
TACs suggesting a [11C]PIB delivery to the pons almost as high as in
the gray matter of the cerebellum. On the other hand, the [11C]PIB
washout from the pons appears to be clearly slower than in the cere-
bellum and in the cortex of the control subject but still faster than in
the white matter as represented by the TACs from the centrumjects with a history of familial Alzheimer's disease (FAD).
Controls
Mean±SD
First case FAD 1 Second case FAD 2
e RATIOPONS RATIOPONS Per cent difference RATIOPONS Per cent difference
0.69±0.06 1.15 66.8 1.01 46.5
0.68±0.09 1.44 111.1 1.09 59.8
0.68±0.06 1.26 84.5 0.93 36.2
0.67±0.06 1.21 79.4 1.02 51.2
0.66±0.06 1.09 64.7 1.01 52.7
0.67±0.06 1.21 79.6 1.10 63.3
0.64±0.07 1.01 58.7 0.96 50.9
1±0 1 0 1 0
rs and a group of 10 control subjects using two simpliﬁed outcome parameters (target
ent target regions and the two reference regions considered.
ge difference, AD denotes the parameter estimated in each of the familial Alzheimer's
nds for standard deviation.
Fig. 2. Parametric images of the target-to-pons ratio RATIOPONS (left) and structural
images (right).In the top row (panel A) the sagittal sections from a control participant
are shown. Superimposed on both the PET and the MR images are the two reference
regions, in yellow the cerebellar gray matter and in magenta the pons, respectively.
Notice the low [11C]PIB binding throughout the brain with only few focal areas of in-
creased binding in white matter.In the middle panel B, the pattern of [11C]PIB binding
in this AD patient is characterised by a RATIOPONS of one or higher in most of the
cortical gray matter. The inserted color bar applies to all three RATIOPONS images
shown on the left hand side.The familial AD subject FAD2 (Table 4) in the bottom sec-
tion (panel C) exhibits rather scattered spots of high [11C]PIB signal not clearly associated
with either gray or white matter. Note that this also includes the cerebellar gray matter.
Fig. 3. Tissue time-activity curves (TACs) in an AD subject (A) and a control (B).In each
case, the TACs for the gray matter cerebellum, the gray matter temporal cortex as an
example for the cortical regions, the pons and the centrum semiovale representing
white matter are shown.
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centration in the pons region is smaller than in the centrum semio-
viale (Fig. 3).
As a consequence of these differential kinetics, the absolute values
of the target-to-reference tissue activity ratios RATIOCER and RATIO-
PONS calculated in the interval from 60 to 90 min are governed by
the relationship between tracer delivery and washout. The pons-to-
cerebellum ratio is approximately 1.5 for controls and AD patients.
The cortex-to-cerebellum ratio can be as high as 2 in AD patients
and is only slightly greater than 1 in controls. Therefore, the cortex-
to-pons ratios are in the order of 1.33 for AD patients and around
0.67 in controls (see Table 1 for a complete list).
The slower clearance of [11C]PIB from the pons than from the
gray matter cerebellum or cortex in control subjects results in larger
pons VT than in those other regions (mean values from Table 1:
VTPons=3.45 ml/cm3 versus VT=2.42 … 2.68 ml/cm3 for the other
regions in the cohort of controls). It is unclear what the reason for
this slightly higher VT in the pons is, however, the higher non-
speciﬁc binding of [11C]PIB in white matter has been suggested to
be due to binding in the myelin sheath which has a very high afﬁnity
for thioﬂavins.
Pons is easier to deﬁne compared to the cerebellum, and could be
delineated even without an MRI scan. Here we have used a semiauto-
matic method to deﬁne cerebellum which requires coregistration
with MRI, segmentation and thresholding, all of which could add
variance. Some studies use manual approach to delineate cerebellum,
which may be associated with increased inter and intra operator
variability.In conclusion, this is the ﬁrst study to evaluate the use of target-
to-pons ratios for the analysis of [11C]PIB brain scans and to assess
the test–retest variability in comparison to the arterial input analysis.
We have demonstrated that the target-to-pons ratio has low test–retest
variability and high reproducibility and can be used as a simpliﬁed
method of quantiﬁcationwhen the use of the cerebellum as a reference
is not conﬁrmed.
References
Aalto, S., Scheinin, N.M., Kemppainen, N.M., Nagren, K., Kailajarvi, M., Leinonen, M.,
Scheinin, M., Rinne, J.O., 2009. Reproducibility of automated simpliﬁed voxel-
based analysis of PET amyloid ligand [11C]PIB uptake using 30-min scanning
data. Eur. J. Nucl. Med. Mol. Imaging 36, 1651–1660.
American Psychiatric Association, 1994. Diagnostic and statistical manual of mental
disorders, Fourth edition, Text revision.
Drzezga, A., Grimmer, T., Henriksen, G., Stangier, I., Perneczky, R., Diehl-Schmid, J.,
Mathis, C.A., Klunk, W.E., Price, J., Dekosky, S., Wester, H.J., Schwaiger, M., Kurz,
A., 2007. Imaging of amyloid plaques and cerebral glucose metabolism in semantic
dementia and Alzheimer's disease. Neuroimage.
Edison, P., Archer, H.A., Hinz, R., Hammers, A., Pavese, N., Tai, Y.F., Hotton, G., Cutler, D.,
Fox, N., Kennedy, A., Rossor, M., Brooks, D.J., 2007. Amyloid, hypometabolism, and
cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology
68, 501–508.
Edison, P., Rowe, C.C., Rinne, J.O., Ng, S., Ahmed, I., Kemppainen, N., Villemagne, V.L.,
O'Keefe, G., Nagren, K., Chaudhuri, R., Masters, C.L., Brooks, D.J., 2008. Amyloid
load in Parkinson's disease dementia and Lewy Body dementia measured with
[11C]PIB-PET. J Neurol Neurosurg Psychiatry.
Edison, P., Brooks, D.J., Turkheimer, F.E., Archer, H.A., Hinz, R., 2009. Strategies for the
generation of parametric images of [11C]PIB with plasma input functions consider-
ing discriminations and reproducibility. NeuroImage 48, 329–338.
Engler, H., Forsberg, A., Almkvist, O., Blomquist, G., Larsson, E., Savitcheva, I., Wall, A.,
Ringheim, A., Langstrom, B., Nordberg, A., 2006. Two-year follow-up of amyloid
deposition in patients with Alzheimer's disease. Brain 129, 2856–2866.
Forsberg, A., Engler, H., Almkvist, O., Blomquist, G., Hagman, G., Wall, A., Ringheim, A.,
Langstrom, B., Nordberg, A., 2007. PET imaging of amyloid deposition in patients
with mild cognitive impairment. Neurobiol Aging.
Ghiso, J., Frangione, B., 2001. Cerebral amyloidosis, amyloid angiopathy, and their
relationship to stroke and dementia. J. Alzheimers Dis. 3, 65–73.
Gomperts, S.N., Rentz, D.M., Moran, E., Becker, J.A., Locascio, J.J., Klunk, W.E., Mathis,
C.A., Elmaleh, D.R., Shoup, T., Fischman, A.J., Hyman, B.T., Growdon, J.H., Johnson,
K.A., 2008. Imaging amyloid deposition in Lewy body diseases. Neurology 71,
903–910.
1723P. Edison et al. / NeuroImage 60 (2012) 1716–1723Gunn, R.N., Lammertsma, A.A., Hume, S.P., Cunningham, V.J., 1997. Parametric imaging
of ligand-receptor binding in PET using a simpliﬁed reference region model. Neu-
roImage 6, 279–287.
Hammers, A., Allom, R., Koepp,M.J., Free, S.L.,Myers, R., Lemieux, L.,Mitchell, T.N., Brooks, D.J.,
Duncan, J.S., 2003. Three-dimensional maximum probability atlas of the human brain,
with particular reference to the temporal lobe. Hum. Brain Mapp. 19, 224–247.
Hinz, R., Turkheimer, F.E., 2006. Determination of tracer arrival delay with spectral
analysis. IEEE Trans. Nucl. Sci. 53, 212–219.
Kaufer, I.D., Yuen, H., DeKosky, S., Klunk, W., 2008. Cerebellar amyloid in a case of early-
onset dementia with a presenilin-1 mutation: correlation to clinical phenotype.
Alzheimer's Dementia 4, T290–T291.
Kemppainen, N.M., Aalto, S.,Wilson, I.A., Nagren, K., Helin, S., Bruck, A., Oikonen, V., Kailajarvi,
M., Scheinin, M., Viitanen, M., Parkkola, R., Rinne, J.O., 2007. PET amyloid ligand [11C]PIB
uptake is increased in mild cognitive impairment. Neurology 68, 1603–1606.
Klunk, W.E., Wang, Y., Huang, G.F., Debnath, M.L., Holt, D.P., Mathis, C.A., 2001. Un-
charged thioﬂavin-T derivatives bind to amyloid-beta protein with high afﬁnity
and readily enter the brain. Life Sci. 69, 1471–1484.
Klunk, W.E., Wang, Y., Huang, G.F., Debnath, M.L., Holt, D.P., Shao, L., Hamilton, R.L.,
Ikonomovic, M.D., DeKosky, S.T., Mathis, C.A., 2003. The binding of 2-(4′-
methylaminophenyl)benzothiazole to postmortem brain homogenates is dom-
inated by the amyloid component. J. Neurosci. 23, 2086–2092.
Klunk, W.E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D.P., Bergstrom, M.,
Savitcheva, I., Huang, G.F., Estrada, S., Ausen, B., Debnath, M.L., Barletta, J., Price, J.C.,
Sandell, J., Lopresti, B.J., Wall, A., Koivisto, P., Antoni, G., Mathis, C.A., Langstrom, B.,
2004. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.
Ann. Neurol. 55, 306–319.
Klunk,W.E., Price, J.C.,Mathis, C.A., Tsopelas, N.D., Lopresti, B.J., Ziolko, S.K., Bi,W., Hoge, J.A.,
Cohen, A.D., Ikonomovic, M.D., Saxton, J.A., Snitz, B.E., Pollen, D.A., Moonis, M., Lippa,
C.F., Swearer, J.M., Johnson, K.A., Rentz, D.M., Fischman, A.J., Aizenstein, H.J., DeKosky,
S.T., 2007. Amyloid deposition begins in the striatum of presenilin-1mutation carriers
from two unrelated pedigrees. J. Neurosci. 27, 6174–6184.
Lockhart, A., Lamb, J.R., Osredkar, T., Sue, L.I., Joyce, J.N., Ye, L., Libri, V., Leppert, D.,
Beach, T.G., 2007. PIB is a non-speciﬁc imaging marker of amyloid-beta (Abeta)
peptide-related cerebral amyloidosis. Brain 130, 2607–2615.
Logan, J., 2000. Graphical analysis of PET data applied to reversible and irreversible
tracers. Nucl. Med. Biol. 27, 661–670.Lopresti, B.J., Klunk, W.E., Mathis, C.A., Hoge, J.A., Ziolko, S.K., Lu, X., Meltzer, C.C.,
Schimmel, K., Tsopelas, N.D., Dekosky, S.T., Price, J.C., 2005. Simpliﬁed quantiﬁcation
of Pittsburgh compound B amyloid imaging PET studies: a comparative analysis.
J. Nucl. Med. 46, 1959–1972.
Mathis, C.A., Bacskai, B.J., Kajdasz, S.T., McLellan, M.E., Frosch, M.P., Hyman, B.T., Holt,
D.P., Wang, Y., Huang, G.F., Debnath, M.L., Klunk, W.E., 2002. A lipophilic
thioﬂavin-T derivative for positron emission tomography (PET) imaging of amy-
loid in brain. Bioorg. Med. Chem. Lett. 12, 295–298.
Mathis, C.A., Wang, Y., Holt, D.P., Huang, G.F., Debnath, M.L., Klunk, W.E., 2003. Synthesis
and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging
agents. J. Med. Chem. 46, 2740–2754.
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M., 1984.
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work
Group under the auspices of Department of Health and Human Services Task
Force on Alzheimer's Disease. Neurology 34, 939–944.
Mead, S., Poulter, M., Beck, J., Webb, T.E., Campbell, T.A., Linehan, J.M., Desbruslais, M.,
Joiner, S.,Wadsworth, J.D., King, A., Lantos, P., Collinge, J., 2006. Inherited prion disease
with six octapeptide repeat insertional mutation–molecular analysis of phenotypic
heterogeneity. Brain 129, 2297–2317.
Price, J.C., Klunk, W.E., Lopresti, B.J., Lu, X., Hoge, J.A., Ziolko, S.K., Holt, D.P., Meltzer,
C.C., DeKosky, S.T., Mathis, C.A., 2005. Kinetic modeling of amyloid binding in
humans using PET imaging and Pittsburgh Compound-B. J. Cereb. Blood Flow
Metab. 25, 1528–1547.
Rabinovici, G.D., Furst, A.J., O'Neil, J.P., Racine, C.A., Mormino, E.C., Baker, S.L., Chetty, S.,
Patel, P., Pagliaro, T.A., Klunk,W.E.,Mathis, C.A., Rosen,H.J.,Miller, B.L., Jagust,W.J., 2007.
11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration.
Neurology 68, 1205–1212.
Ranicar, A.S., Williams, C.W., Schnorr, L., Clark, J.C., Rhodes, C.G., Bloomﬁeld, P.M., Jones,
T., 1991. The on-line monitoring of continuously withdrawn arterial blood during
PET studies using a single BGO/photomultiplier assembly and non-stick tubing.
Med. Prog. Technol. 17, 259–264.
Watanabe, R., Duchen, L.W., 1993. Cerebral amyloid in human prion disease. Neuropathol.
Appl. Neurobiol. 19, 253–260.
Yaqub, M., Tolboom, N., Boellaard, R., van Berckel, B.N., van Tilburg, E.W., Luurtsema, G.,
Scheltens, P., Lammertsma, A.A., 2008. Simpliﬁed parametric methods for [(11)C]
PIB studies. NeuroImage 42, 76–86.
